Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MEI Pharma, Inc. (MEIP) Starts Presentation at 25th Annual ROTH Conference

Posted on March 19, 2013 by Mission IR

MEI Pharma is engaged in the clinical development of novel therapies for cancer. The company’s lead drug candidate is Pracinostat inhibitor is being developed for advanced hematologic malignancies such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). MEIP plans to initiate a randomized, placebo-controlled phase II trial of Pracinostat in combination with azacitidine in patients with MDS by June 2013. For more information, visit the company’s Web site: http://www.meipharma.com

Let us hear your thoughts below:

This year's annual ROTH Conference will take place at The Ritz Carlton located in Laguna Niguel, on March 17-12, 2013. Bringing together executives from more than 400 growth companies, the ROTH Conference is one of the largest of its kind in the U.S. For more information on ROTH Capital Partners, visit www.roth.com.
This entry was posted in ROTH Capital Partners Conference. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *